8-K

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION


                             Washington, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT


     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): April 7, 2005


                       PROTEIN POLYMER TECHNOLOGIES, INC.
             (Exact name of registrant as specified in its charter)



             Delaware                      0-19724               33-0311631
- ----------------------------------- ----------------------- --------------------
  (State or other jurisdiction of        (Commission           (IRS Employer
   incorporation or organization)        File Number)        Identification No.)

- --------------------------------------------------------------------------------

     10655 Sorrento Valley Road, San Diego, California             92121
- ----------------------------------------------------------- --------------------
         (Address of principal executive offices)                (Zip Code)

- --------------------------------------------------------------------------------

       Registrant's telephone number, including area code: (858) 558-6064
                                                           ---------------------


                                 Not Applicable
- --------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)



================================================================================








Item 5.02. Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.


        On April 7, 2005, at a meeting of the Board of Directors, J. Thomas
Parmeter vacated his position as Chief Executive Officer of Protein Polymer
Technologies, Inc. (the "Company"). He will remain as a full-time employee in
his role as the Chairman of the Board of Directors.

        At the same meeting, the Board of Directors of the Company appointed
William N. Plamondon as Chief Executive Officer to replace Mr. Parmeter in that
office.

        Mr. Plamondon's business experience during the past five years as well
as his other directorships held in reporting companies is fully set forth in
Exhibit 99.1 to the Company's Current Report on Form 8-K filed with the
Securities and Exchange Commission on March 29, 2005 and in Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by reference in its
entirety.

        The Company has not yet entered into a formal agreement for the
employment of Mr. Plamondon. However, the Board of Directors provided that the
Company will pay $300,000 annually, at the rate of $25,000 per month, to Mr.
Plamondon's affiliated consulting company, R.I. Heller & Co., LLC. In addition,
the Board of Directors also provided that Mr. Plamondon would receive rights to
acquire 2,000,000 shares of the Company's common stock, the terms of which are
to be determined by the compensation committee of the Board of Directors.

        The Company has issued a press release which details the above-mentioned
events. A copy of the press release is filed as Exhibit 99.1 to this Current
Report.

Item 9.01.  Financial Statements and Exhibits.

        (c)    Exhibits.

               99.1          Press Release of Protein Polymer Technologies, Inc.
                             dated April 11, 2005








                                    SIGNATURE

               Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                               PROTEIN POLYMER TECHNOLOGIES, INC.,
                               a Delaware corporation


Date: April 13, 2005           By: /s/ J. Thomas Parmeter
                                   ---------------------------------------------
                                   J. Thomas Parmeter
                                   Chairman of the Board







                                  EXHIBIT INDEX

Exhibit No.           Description
- -----------           -----------

99.1                  Press Release of Protein Polymer Technologies, Inc. dated
                      April 11, 2005

EX-99

                                                                    Exhibit 99.1


                                                           FOR IMMEDIATE RELEASE

CONTACTS:
J. Thomas Parmeter
Chairman
(858) 558-6062
info@ppti.com


PROTEIN POLYMER TECHNOLOGIES SELECTS WILLIAM N. PLAMONDON III AS NEW CHIEF
EXECUTIVE OFFICER

        SAN DIEGO, April 11, 2005 -- Protein Polymer Technologies, Inc. (OTC BB:
PPTI) announced today the appointment of William N. Plamondon III as its new
Chief Executive Officer. J. Thomas Parmeter, PPTI's former CEO, will remain in
his capacity as Chairman of the Board of Directors, and Donald Kaplan, Ph.D.
will continue as President and Chief Operating Officer.

        "Bill Plamondon has been an advisor to PPTI for the last seven months
and was recently named to the Board of Directors. The addition of Bill to our
management team adds a very broad base of business experience to our
capabilities. Over the course of his career, Bill has served as CEO for several
public and private companies," said J. Thomas Parmeter, PPTI's Chairman. "His
skills and insight will add great value to PPTI's future."

        In his leadership roles, Mr. Plamondon has been the CEO of companies
exceeding $3 billion of revenue worldwide. He has successfully driven
acquisitions and reorganizations, in addition to building and growing businesses
in a variety of industries. Bill Plamondon is currently President and CEO of
R.I. Heller & Co., LLC, a management consulting firm, and serves on the Board of
Directors of several companies, charities and non-profit organizations.

        "I look forward to helping a great team of people with outstanding
scientific accomplishments continue to build a great company," Mr. Plamondon
said, following the announcement of his new role.

        Protein Polymer Technologies, Inc., is a San Diego-based company focused
on developing products to improve medical and surgical outcomes. From its
inception in 1988, PPTI has been a pioneer in protein design and synthesis,
creating an extensive portfolio of proprietary biomaterials for use in the
development of bioactive devices. These genetically engineered biomaterials are
high molecular weight proteins, processed into products with physical and
biological characteristics tailored to specific clinical performance
requirements. Targeted products include urethral bulking agents for the
treatment of stress urinary incontinence, dermal augmentation products for
cosmetic and reconstructive surgery, surgical adhesives and sealants, scaffolds
for wound healing and tissue engineering, and depots for local drug delivery. To
date,







PPTI has been issued twenty-six U.S. Patents on its core technology with
corresponding issued and pending patents in key international markets.

        This press release contains forward-looking statements that are based on
management's views and expectations. Actual results could differ materially from
those expressed here; further, the Company is not obligated to comment
specifically on those differences. Risks associated with the Company's
activities include raising adequate capital to continue operations, scientific
and clinical product development uncertainties, competitive products and
approaches, continuing collaborative partnership interest and funding,
regulatory testing and approvals, and manufacturing scale-up. The reader is
encouraged to refer to the Company's 2004 Annual Report on Form 10-KSB, and
other recent filings with the Securities and Exchange Commission, copies of
which are available from the Company, to further ascertain the risks associated
with the above statements.